New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
10:03 EDTEA, CHD, MS, HRC, ITRI, SLW, PVA, DO, PDCE, MMC, DELL, EXPR, GCI, CG, AGNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Outperform from Market Perform at JMP Securities... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Dell (DELL) upgraded to Neutral from Sell at Citigroup... Express (EXPR) upgraded to Overweight from Neutral at JPMorgan... Gannett (GCI) upgraded to Buy from Neutral at Citigroup... Marsh & McLennan (MMC) upgraded to Buy from Neutral at Goldman... PDC Energy (PDCE) upgraded to Buy from Hold at Miller Tabak... Diamond Offshore (DO) upgraded to Outperform from Sector Perform at Iberia... Penn Virginia (PVA) upgraded to Outperform from Sector Perform at Howard Weil... Silver Wheaton (SLW) upgraded to Outperform from Neutral at Credit Suisse... Itron (ITRI) upgraded to Buy from Hold at Argus... Hill-Rom (HRC) upgraded to Conviction Buy from Buy at Goldman... Morgan Stanley (MS) upgraded to Neutral from Reduce at SunTrust... Church & Dwight (CHD) upgraded to Outperform from Underperform at CLSA... Electronic Arts (EA) upgraded to Buy from Neutral at Sterne Agee.
News For AGN;CG;GCI;EXPR;DELL;MMC;PDCE;DO;PVA;SLW;ITRI;HRC;MS;CHD;EA From The Last 14 Days
Check below for free stories on AGN;CG;GCI;EXPR;DELL;MMC;PDCE;DO;PVA;SLW;ITRI;HRC;MS;CHD;EA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 16, 2014
15:02 EDTMSMorgan Stanley July 32.5 straddle priced for 3.3% move into Q2
Subscribe for More Information
14:57 EDTMSEarnings Preview: Morgan Stanley to report amid optimism on Wealth Management
Morgan Stanley (MS) is scheduled to report second quarter earnings before the open on Thursday, July 17 with a conference call scheduled for 10:00 am ET. Morgan Stanley is a bank holding company. EXPECTATIONS: Analysts are looking for EPS of 55c on revenue of $8.2B, according to First Call. The consensus range for EPS is 52c-64c on revenue of $7.58B-$8.65B. Morgan Stanley (MS) reported stronger than expected first quarter results, as the company's revenue rose to $8.9B from $8.2B. The company's wealth management unit generated pre-tax income of $691M, versus $597M in the same period a year earlier. Morgan Stanley's investment management unit saw its pre-tax income from continuing operations rise to $263M from $187M, while the pre-tax income of its institutional Securities division rose $1.4B, up from $799M. Morgan Stanley's wealth management business will continue growing and the business' return on equity will eventually be well over 10%, said the company's CEO, Tom Gorman last month, according to The New York Times. But declines in the bank's fixed income revenues may make it harder for its securities businesses to exceed a 10% return on equity, and the firm has significantly reduced its trading operations, the newspaper quoted the CEO as saying. PEERS: On July 15, Goldman Sachs reported stronger than expected results, as the bank's investment banking unit saw its net revenue rise 15% year-over-year, while the net revenues generated by its Institutional Client Services unit dropped 11%. But Goldman's investing and lending unit saw its net revenues surge 46% year-over-year. Citigroup (C), on July 14, reported higher than expected Q2 EPS excluding certain items but lower than expected revenue. Revenue from Citi's Institutional Client Group dropped 11%, as revenue from fixed income and equity markets fell. STREET RESEARCH: On July 10, research firm Bernstein recommended Morgan Stanley's stock due to its exposure to high margin investment banking. Bernstein also liked Morgan Stanley because of its exposure to wealth management. PRICE ACTION: Morgan Stanley is up almost 9% over the last three months and it has surged over 23% in the last twelve months.
10:36 EDTAGNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:31 EDTAGNPershing Square Capital Management holds analyst/industry conference call
Subscribe for More Information
09:16 EDTAGNPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allergan’s corporate governance.
09:03 EDTEAElectronic Arts price target raised to $44 from $37 at Sterne Agee
Subscribe for More Information
08:16 EDTAGNLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTAGNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
11:13 EDTAGNPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTDOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTDODiamond Offshore upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
06:06 EDTEAElectronic Arts names Ken Moss as Chief Technology Officer
Electronic Arts (EA) announced on its website that it has named Ken Moss as its Chief Technology Officer. As CTO, Ken will lead the organization, strategy and vision for EA’s Digital Platform and Information Technology divisions. Moss comes to EA most recently from eBay (EBAY), where he led the Marketplace Technology, Science and Data global organization. He is a 20-year veteran of Microsoft (MSFT), where he founded and led the engineering and product teams on Search -- which later became Bing -- and played an important role in Microsoft’s transition to large-scale services. Reference Link
July 14, 2014
12:47 EDTAGNAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:46 EDTITRIItron selects Microsoft Azure as preferred cloud platform
Subscribe for More Information
08:13 EDTAGNAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTAGNValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
July 11, 2014
16:48 EDTAGNAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
11:54 EDTAGNAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
07:34 EDTMSMorgan Stanley July volatility elevated into Q2 and outlook
Subscribe for More Information
07:20 EDTMSBig banks seen losing reserve release cushion, Reuters says
Releasing loan-loss reserves has helped U.S. big banks weather a period of weak loan demand and lower fee income, but Q2 results from the banks may see less benefit from the practice as loss rates and reserves near their lower limits, said Reuters. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use